Journal article icon

Journal article

Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study

Abstract:

Background Gemcitabine is used to treat a wide range of tumours but its efficacy is limited by cancer cell resistance mechanisms. NUC-1031, a phosphoramidate modification of gemcitabine, is the first anti-cancer ProTide to enter the clinic and is designed to overcome these key resistance me...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's Version

Actions


Access Document


Files:
Publisher copy:
10.1038/s41416-018-0244-1

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences
Department:
Oncology
Oxford college:
Hertford College
ORCID:
0000-0001-8783-3491
Rizzuto, I More by this author
Suppiah, P More by this author
Expand authors...
Imperial College London More from this funder
Publisher:
Nature Publishing Group Publisher's website
Journal:
British Journal of Cancer Journal website
Volume:
119
Pages:
815–822
Publication date:
2018-09-12
Acceptance date:
2018-08-02
DOI:
EISSN:
1532-1827
ISSN:
1532-1827
Pubs id:
pubs:910996
URN:
uri:b391c4c8-5460-4ae7-b8cd-f528854130c0
UUID:
uuid:b391c4c8-5460-4ae7-b8cd-f528854130c0
Local pid:
pubs:910996

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP